Ionis Pharmaceuticals, Inc. Common Stock
Market cap $6.6B
$39.42
IONS
$39.42
+1.60% today
Buy with €1M virtual cash · No real money
Ionis Pharmaceuticals, Inc. Common Stock (IONS) is a publicly traded company listed on the XNAS. As of November 8, 2026, Invest's signal rates IONS a Sell, with the stock down 47% over the past year. You can practice trading IONS risk-free with €1,000,000 in virtual cash.
Key stats
As of November 8, 2026
Market Cap
$6.6B
Volume
2.9M
52-wk High
$86.74
52-wk Low
$38.31
Day High
$40.00
Day Low
$38.53
Performance
1M
-9.0%
6M
-47.9%
1Y
-47.2%
Invest signal · IONS
SellAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
IONS overview
AI overviewLatest IONS news
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Investment Research · Oct 29
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
Zacks Investment Research · Oct 28
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Zacks Investment Research · Oct 27
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
GlobeNewswire Inc. · Oct 23
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
The Motley Fool · Oct 21
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023.
Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Employees
1,402
30-Day Win Rate · IONS
11 days
13 days
Last 24 sessions
How to practice trading IONS
- 1
Use the IONS buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top IONS traders on Invest
Full leaderboardFrequently asked questions
Is IONS a good stock to buy right now?
As of November 8, 2026, Invest's signal rates IONS a Sell, based on its price trend, valuation, and fundamentals, with the stock down 47% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading IONS risk-free first.
What is Ionis Pharmaceuticals, Inc. Common Stock's (IONS) market cap?
Ionis Pharmaceuticals, Inc. Common Stock has a market capitalization of approximately $6.6B.
How has IONS stock performed?
IONS is down 47% over the past year and down 48% over six months. Its 52-week range runs roughly from $38.31 to $86.74. Past performance doesn't predict future results.
How can I practice trading IONS for free?
On Invest you get €1,000,000 in virtual cash and can buy IONS at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.